EUS-RFA Versus Surgery for Pancreatic Insulinoma (ERASIN-RCT) — ERASIN-RCT

Pancreatic Insulinoma Clinical Trial

Official title:
Endoscopic Ultrasound-guided RAdiofrequency Ablation Versus Surgical Resection for the Treatment of Pancreatic INsulinoma: a Multicenter Randomized Controlled Trial

Status Recruiting

Clinical Trial Summary

The goal of this muticentre randomized controlled trial is to compare endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) with surgery for treatment of pancreatic insulinoma. The main questions it aims to answer are: 1) What is the safest treatment? 2) Is efficacy comparable? Patients will be randomized to undergo EUS-RFA or surgical resection. Researchers will compare the rate of adverse events and the clinical efficacy after the two treatments to see if EUS-RFA result safer and effective compare with surgery.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05735912
Study type	Interventional
Source	Azienda Ospedaliera Universitaria Integrata Verona
Contact	Stefano Francesco Crinò, MD
Phone	00390458126191
Email	stefanofrancesco.crino@aovr.veneto.it
Status	Recruiting
Phase	N/A
Start date	March 1, 2023
Completion date	February 28, 2029

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01204476` - Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma	Phase 1
Completed	`NCT00454363` - Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer	Phase 2
Withdrawn	`NCT02831179` - Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor	Phase 1